Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Appropriate Antibiotic Use for Acute Otitis Media
Your Article Summary
Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses
Cancer, 07/31/09
Homma A et al. - In a study to evaluate the efficacy of superselective high-dose cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated pts with advanced cancer of the nasal cavity and paranasal sinuses, it was found that, although a single institution experience, results suggest that RADPLAT can cure the majority of pts with advanced cancer of the nasal cavity and paranasal sinuses, as well as preserve organs.
Methods- 47 pts were given superselective intra-arterial infusions of cisplatin (100-120 mg/m2/wk) with simultaneous intravenous infusions of thiosulfate to neutralize cisplatin toxicity and conventional external-beam radiotherapy (65-70 grays).
- There were 7 pts (14.9%) diagnosed with T3, 22 (46.8%) with T4a, and 18 (38.3%) with T4b disease.
- During the median follow-up period of 4.6 yrs, 5-yr local progression-free survival rate was 78.4% for all pts (n=47), 69.0% for pts with T4b disease (n=18), and 83.2% for pts with
- 5-yr overall survival rate was 69.3% for all pts, 61.1% for pts with T4b disease, and 71.1% for pts with
- RADPLAT was feasible in 45 pts (95.7%).
- No pt died as a result of treatment toxicity or had a cerebrovascular accident.
- Osteonecrosis (n=7), brain necrosis (n=2), and ocular/visual problems (n=16) were observed as late adverse reactions.
- 5-yr overall survival rate was 69.3% for all pts, 61.1% for pts with T4b disease, and 71.1% for pts with
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Saline Nasal Irrigation for Upper Respiratory Conditions
American Family Physician, 11/12/09
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
The Lancet Oncology - Online First, 11/12/09
Clinical Studies of Combination Montelukast and Loratadine in Patients with Seasonal Allergic Rhinitis
Journal of Asthma, 11/11/09
Today in Nose...keeping you current
Receive free subspecialty "5-minute updates" via email
Role of adenoids and adenoiditis in children with allergy and otitis media
Current Allergy and Asthma Reports, 10/22/09
Montelukast in the treatment of asthma and beyond
Expert Review of Clinical Immunology, 11/23/09
Saline Nasal Irrigation for Upper Respiratory Conditions
American Family Physician, 11/12/09
Today in Sinus...keeping you current
Receive free subspecialty "5-minute updates" via email
Bone chip-induced rhinosinusitis
The Laryngoscope, 11/02/09
Characterization of initial clinical symptoms and risk factors for sinonasal adenocarcinomas: results of a case-control study
International Archives of Occupational & Environmental Health, 11/06/09
Endonasal Endoscopic Management of Contact Point Headache and Diagnostic Criteria
Headache: The Journal of Head and Face Pain, 10/07/09
Article Search
Sponsor


See Latest Articles


